SlideShare a Scribd company logo
Education & Advocacy Track:
Parent Advocates
Moving Legislation
Presenters:
• Karen H. Perry, Co-Founder and Executive Director, Narcotics
Overdose Prevention and Education (NOPE) Task Force, and
Member, Rx Summit National Advisory Board
• Gary R. Martin, EdD, Dean of Students, Lynn University, and
Vice President, NOPE Task Force
• Charlotte Wethington, MA, Recovery Advocate, Transitions, Inc.
Moderator: Michael C. Barnes, JD, Executive Director, Center for
Lawful Access and Abuse Deterrence (CLAAD), and Member, Rx
Summit National Advisory Board
Disclosures
• Karen H. Perry; Gary R. Martin, EdD; Charlotte Wethington;
and Michael C. Barnes, JD, have disclosed no relevant, real,
or apparent personal or professional financial relationships
with proprietary entities that produce healthcare goods and
services.
Disclosures
• All planners/managers hereby state that they or their
spouse/life partner do not have any financial
relationships or relationships to products or devices
with any commercial interest related to the content of
this activity of any amount during the past 12 months.
• The following planners/managers have the following to
disclose:
– Kelly Clark – Employment: Publicis Touchpoint Solutions;
Consultant: Grunenthal US
– Robert DuPont – Employment: Bensinger, DuPont &
Associates-Prescription Drug Research Center
– Carla Saunders – Speaker’s bureau: Abbott Nutrition
Learning Objectives
1. Identify state laws enacted as the result of
parental advocacy.
2. Explain the purpose and components of the
Overdose Prevention Act.
3. Describe Casey’s Law for involuntary
treatment, as well as its passage, impact and
applicability to other states.
Parent Advocates Moving
Legislation
Karen H. Perry
Co-Founder, Executive Director
NOPE Task Force
Gary R. Martin, Ed.D
Dean of Students, Lynn University
Disclosure Statement
Karen Perry and Gary Martin
have no financial relationships with
proprietary entities that produce
health care goods and services
Learning Objectives
1. Identify state laws enacted as the result of
parental advocacy.
2. Explain the purpose and components of the
Overdose Death Prevention Act- “Richie’s
Law”
3. Describe Casey’s Law for involuntary
treatment, as well as its passage, impact and
applicability to other states.
Richard Perry
Age 21
FloridaHospitalConsenttoTreatment
Hospital Release Orders
Facts
• In 2013, there were 35,663 unintentional
drug overdose deaths in the United
States.
(Source: Center for Disease Control)
• 2.5 million emergency department visits
are attributed to drug misuse or
overdose.
(Source: Drug Abuse Warning Network (DAWN), 2011 National ED
Estimates)
• 26.8% of the people who died from a
drug overdose had experienced a prior
drug overdose with a hospital visit. (Source:
Palm Beach County Sheriff’s Office Overdose Suppression Project 2013)
• 82.3 % of the decedents had a known
substance abuse history
(Source: Palm Beach County Sheriff’s Office Overdose Suppression Project
2013)
• 51.3 % of the decedents were under the
care of a physician
(Source: Palm Beach County Sheriff’s Office Overdose Suppression Project
2013)
Heart Attack Victim Care
The first 24 hours following a heart attack are usually spent in
a coronary care unit (CCU) or an intensive care unit(ICU).
Where skilled staff will:
•Continuously monitor your heart rhythm
•Administer a series of test and blood work
•Administer medication as needed
•Review patient’s history
•Contact primary care and/or cardiac care physicians
Cardiac Care Day Two
If you remain stable after 24 hours
You may be transferred to the
"telemetry" floor of the hospital
• Continue to receive care by a
cardiac care team.
• Depending upon the severity of
the heart attack and how quickly
you received treatment, you may
be able to go home within two to
four days.
Overdose Patient
Treat and Street
Intervention Point
Overdose Death Prevention Act
(ODPA)
A bill that requires specific
rules that would apply to
an emergency care
practitioner when the
patient suffers a non-fatal
unintentional overdose.
ODPA Rules and Procedures
• Proper medical
stabilization (detox)
• Substance Abuse
Screening Brief
Intervention and
Referral to Treatment
(SBIRT)
ODPA Rules and Procedures
• Notify patient’s
primary care physician.
• Notify all patient’s
prescribing doctors
within last 12 months.
ODPA Rules and Procedures
• Notify the patient’s
emergency contact or next
of kin.
• Provide materials on
addiction treatment,
treatment facilities and
practitioners.
• Provide local involuntary
treatment laws.
HIPAA
The HIPAA law currently indicates that emergency room
physicians may notify next of kin if they feel it important
or necessary for survival of the patient.
This linked-document (authored by the U.S. Department of Health and
Human Services) provides a summary of the HIPAA Privacy
Rule. http://www.hhs.gov/ocr/privacy/hipaa/understanding/summary/in
dex.html
HIPAA
Federal Register-Volume 65. No. 250 (12-28-2000) Section
164.502(g) – Personal Representatives
“We continue to allow covered entities to use their discretion
to disclose certain protected health care information to
family members, relatives, close friends, and other persons
assisting in the care of an individual, in accordance with
164.510(b). We recognize that many health care decisions
take place on an informal basis, and we permit disclosures in
certain circumstance to permit this practice to continue.
Health care providers may continue to use their discretion to
address these informal situations” (p. 82501).
Readmissions
Because Centers for Medicare
& Medicaid Services will
penalize hospitals that see
too many patients return
within a month, now is the
time to create strategies to
avoid readmissions.
Local Overdose Death Data
247 drug overdose
deaths in Palm Beach
County in the year 2012
• More than Suicides
• More than Homicides
• More than Fatal Car
Accidents
Combining and Mixing Drugs
• Multiple contributable
drugs found in majority
of overdose fatalities
• Average of 2.7 drugs
found in overdose cases
81
66
41
231
54
84
11
0
50
100
150
200
250
Cocaine Alcohol OTC Prescription Drugs
Only
Illicit Drugs Only Prescription and
Illicit Drugs
Not Toxicology
NumberofDecedentswithDruginToxicology
Toxicology Findings
Compiled from 304 Closed Overdose Death Investigations
2
9
78
51
78
69
11
1
3
0
2
0
10
20
30
40
50
60
70
80
90
0-10 11-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 90-100 Unknown
NumberofDecedents
Years of Age
Decedent's Age
Data Compiled from 304 Closed Overdose Death Investigations
82.57%
43.09%
36.18%
22.04%
26.64%
20.72% 18.75%
51.32%
15.79%
33.22%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
Substance
Abuse
History
Substance
Abuse
Treatment
Drug Related
Arrest
Suicide
Attempt
Non-Fatal
Overdose
Marchman
Baker Act
Bipolar
Diagnosis
Receiving
Medical
Treatment
Pain
Management
Patient
Employed at
Time of
Death
Decedent's History
Data Compiled from 304 Closed Death Investigations
40.13%
32.57%
67.76%
38.16%
59.87%
48.68%
35.20%
17.43%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
Died in
Municipality
Taken to Hospital Died at Home Discovered by
Family
Died While Others
Present
Others Aware of
Fatal Drug Use
Others Recognized
Victim's Distress
Unusual Snoring
Heard
Circumstantial Variables
Data Compiled from 304 Closed Overdose Death Investigations
Education and Advocacy
 Be informed of local
issues
 Build relationships
 Educate Legislators and
community partners
 Create tool kit for
community partners
 Attend and provide
testimonials at
important legislative
meetings
Contact Information
Karen H. Perry
NOPE Task Force
561-478-1055 x201
kperry@nopetaskforce.org
Gary Martin, Ed.D.
Lynn University
561-237-7157
gmartin@lynn.edu
Parent Advocates
Moving Legislation
Charlotte Wethington, MA
Recovery Advocate
Transitions, Inc.
Disclosures
• Charlotte Wethington, MA, has disclosed no relevant, real, or
apparent personal or professional financial relationships with
proprietary entities that produce healthcare goods and
services.
Casey’s Story
Passion
Purpose
Matthew Casey Wethington Act
for Substance Abuse Intervention
What is Casey’s Law?
• An involuntary
treatment act in
Kentucky for those
who suffer from the
disease of addiction
History of the Act
• Became a law on April 9, 2004
• Became effective July 13, 2004 in
Kentucky
• Inspired by the death of Matthew Casey
Wethington, who died of a heroin
overdose at the age of 23
What does this
law provide?
Who can use the
law?
• A means of
intervening with
someone who is
unable to recognize
his or her need for
treatment due to their
impairment
• Parents, relatives
and/or friends can
petition the court for
treatment on behalf of
the person who is
impaired
First Step
• Obtain the petition
from:
– Your local Circuit
Court Clerk’s Office –
ask for Ask for the
Verified Petition for
Involuntary Treatment
(Alcohol/Drug Abuse)
otherwise known as
form AOC 700A
– www.caseyslaw.org
Definitions for Completing the
Petition
Respondent Petitioner
• The person needing
substance abuse
intervention
• The person seeking
to involuntarily
commit someone
else into treatment
Steps for Completing the Petition
• Step One: Enter the Respondent’s name,
address and physical residence
• Step Two: Enter Petitioner’s name,
address and physical residence
• Check box that corresponds with
Petitioner's relationship to the Respondent
• Step Three: Check box that corresponds
with Petitioner's relationship to the
Respondent
Steps for Completing the Petition
• Step Four: List the name, address and
residence of persons related to the
Respondent
• Step Five: Provide all evidence Petitioner
has that Respondent has an alcohol/drug
abuse issue
• Step Six: Attach additional sheets of
paper if needed
Evidence for Alcohol/Drug Abuse
• Witnessing
intoxication
• Witnessing drug use
• Behavioral changes
• Failing drug screens
• Criminal substance
abuse charges
• Theft
• Track marks
• Loss of interest
• Occupational, social
issues
• Admitting
alcohol/drug issue
• Changes in physical
appearance
Steps for Completing the Petition
• Step Seven: Provide all evidence to
support why Petitioner believes the
Respondent is a danger or threat of
danger to self, family or others
• Attach additional sheets of paper if needed
Evidence of Threat
• Respondent has threatened or talked of
suicide
• Respondent has threatened or talked of
harming others (homicide)
• Respondent is unable to provide basic
survival needs (homeless, unemployed)
• History of driving while intoxicated
• Theft (breaking into homes, stealing from
others…)
• History of Overdose
Steps for Completing the Petition
• Indicate what length of treatment the Petitioner is
seeking
• Involuntary treatment for:
– 60 consecutive days or less
– 360 consecutive days or less
• Sign and date the petition
• Swear before the Court Clerk (staff) that all in the petition
is true
• Petition is then presented to a District Court Judge
• The District Court Judge will then decide if there is just
cause to continue with the petition
The Final Step in Filing
• By signing the petition, the petitioner
guarantees payment for ALL COSTS
incurred on behalf of the respondent
• This includes but is not limited to the initial
evaluations, transportation and placement
in a treatment program
What Now?
• If the Judge agrees that there is just cause
he/she will:
• Set a hearing date
• Order the Respondent to be examined by
both a Licensed Physician and a Qualified
Health Professional (Psychiatrist, CADC,
LCSW, LRN)
** (Most counties require the names of the
two evaluators upon filing the petition) **
The Hearing
• The hearing must be conducted within 14
days of the Petition being signed by the
Judge
• The Judge can chose to set the date sooner
if the examinations can be completed
• Or the Judge can extend the hearing date if a
problem with the evaluations arise
• The Respondent will be represented by legal
counsel on the day of the hearing
Summons of Involuntary Treatment
• The Respondent is then notified to attend
both examinations and to appear at the
scheduled hearing
• The Respondent can request that a Qualified
Health Professional (at the Respondents
expense) be permitted to witness and
participate in their examinations
• The Respondent is also notified that failure to
comply with this summons may result in
being held in contempt of court
Appointment of Counsel
• A public defender is appointed to
represent the Respondent and is obligated
to represent the desires of the Respondent
Examinations
• The Petitioner is responsible for the cost
and the selection of the two evaluators,
one of which must be a physician
• Have the examination appointments set
when filing the petition
• If the Respondent does not keep the
scheduled appointments he/she can be
held in contempt of court
Examinations
• The Judge may order that the Respondent
be held on a 72 hour hold if he/she feels
the Respondent is in imminent danger
• The Petitioner is responsible for all fees
associated with the cost of evaluations
Certification of Qualified Health
Professional
• This form is completed by the professional
completing each examination
• It is then sent to the court no longer than
twenty-four (24) hours prior to the hearing
• This also provides the professional’s
recommendations for treatment
At the Hearing
• The Judge will examine all evidence
including but not limited to:
– Respondent’s testimony
– Petitioner’s testimony
– Examination reports
Judgment and Order for Involuntary
Treatment
The Court will be looking for three things:
1. Does the Respondent suffer from
alcohol and/or other drug abuse; and
2. Does the Respondent present an
imminent threat of danger to self, family or
others as a result of alcohol and other
drug abuse; and
3. Can the Respondent reasonably
benefit from treatment?
Judgment and Order for Involuntary
Treatment
• If the Judge feels that all three criteria are
met, then the Judge will order treatment
• Since the Petitioner is responsible for
payment of any ordered treatment, the
Petitioner also chooses where the
Respondent will complete treatment
Judgment and Order for Involuntary
Treatment
• The Judge determines who will be
responsible for transportation of the
Respondent to the treatment program
• If the Judge orders the Sheriff’s office to
transport, then the Petitioner may be
responsible for reimbursement to the
Sheriff’s office for the cost of transportation
Noncompliance
• So what happens if the Respondent fails
to complete anyone of these steps?
• The respondent may be held in Contempt
of Court
• Contempt of Court is punishable in jail by
any length of time the Judge sets each
time the Respondent does not complete
the Judge’s orders
Passion + Purpose + Persistence= Power
7
BE
PERSISTENT
5
CREATE
A
PLAN4
IDENTIFY
YOUR
MISSION
3
FIND
ALLIES
2
DEFINE
YOUR
PURPOSE
1
HONOR
YOUR
PASSION
THE SKY’STHELIMIT
6
TAKE
ACTION
Charlotte Wethington, M.A.
Recovery Advocate
Transitions Inc.
cwethington@transitionsky.org
http://caseyslaw.org/
https://www.facebook.com/caseywethingtonact

More Related Content

What's hot

Rx16 vs nadcp_tues_800_1_walton
Rx16 vs nadcp_tues_800_1_waltonRx16 vs nadcp_tues_800_1_walton
Rx16 vs nadcp_tues_800_1_walton
OPUNITE
 
Dr Sabet Power Point Final Sept 23, 2013
Dr Sabet Power Point Final Sept 23, 2013Dr Sabet Power Point Final Sept 23, 2013
Dr Sabet Power Point Final Sept 23, 2013
Heidi Denton
 
Rx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorinRx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorin
OPUNITE
 
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
OPUNITE
 
Rx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gormanRx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gorman
OPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
OPUNITE
 
Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill ...
Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill ...Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill ...
Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill ...
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Rx16 pharma tues_1230_1_ashley
Rx16 pharma tues_1230_1_ashleyRx16 pharma tues_1230_1_ashley
Rx16 pharma tues_1230_1_ashley
OPUNITE
 
Rx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2wallerRx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2waller
OPUNITE
 
Web only rx16 len-tues_330_1_kougasian-sakacs_2niedermann
Web only rx16 len-tues_330_1_kougasian-sakacs_2niedermannWeb only rx16 len-tues_330_1_kougasian-sakacs_2niedermann
Web only rx16 len-tues_330_1_kougasian-sakacs_2niedermann
OPUNITE
 
Telemedicine Business and Legal Considerations (handouts)
Telemedicine Business and Legal Considerations (handouts)Telemedicine Business and Legal Considerations (handouts)
Telemedicine Business and Legal Considerations (handouts)
VSee
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
OPUNITE
 
Rx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3greenRx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3green
OPUNITE
 
Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
OPUNITE
 
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armaganRx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
OPUNITE
 
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonRx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
OPUNITE
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
OPUNITE
 
Rx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisherRx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisher
OPUNITE
 
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonickRx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
OPUNITE
 

What's hot (20)

Rx16 vs nadcp_tues_800_1_walton
Rx16 vs nadcp_tues_800_1_waltonRx16 vs nadcp_tues_800_1_walton
Rx16 vs nadcp_tues_800_1_walton
 
Dr Sabet Power Point Final Sept 23, 2013
Dr Sabet Power Point Final Sept 23, 2013Dr Sabet Power Point Final Sept 23, 2013
Dr Sabet Power Point Final Sept 23, 2013
 
Rx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorinRx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorin
 
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
 
Rx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gormanRx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gorman
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill ...
Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill ...Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill ...
Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill ...
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 pharma tues_1230_1_ashley
Rx16 pharma tues_1230_1_ashleyRx16 pharma tues_1230_1_ashley
Rx16 pharma tues_1230_1_ashley
 
Rx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2wallerRx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2waller
 
Web only rx16 len-tues_330_1_kougasian-sakacs_2niedermann
Web only rx16 len-tues_330_1_kougasian-sakacs_2niedermannWeb only rx16 len-tues_330_1_kougasian-sakacs_2niedermann
Web only rx16 len-tues_330_1_kougasian-sakacs_2niedermann
 
Telemedicine Business and Legal Considerations (handouts)
Telemedicine Business and Legal Considerations (handouts)Telemedicine Business and Legal Considerations (handouts)
Telemedicine Business and Legal Considerations (handouts)
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3greenRx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3green
 
Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armaganRx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
Rx16 pdmp tues_200_1_o_neill_2carter_3small_armagan
 
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonRx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Rx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisherRx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisher
 
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonickRx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
 

Viewers also liked

Advocacy presentation
Advocacy presentationAdvocacy presentation
Advocacy presentation
Jennifer Hudson Taylor
 
What Would Steve Do? Lessons from the World's Most Captivating Presenters
What Would Steve Do? Lessons from the World's Most Captivating PresentersWhat Would Steve Do? Lessons from the World's Most Captivating Presenters
What Would Steve Do? Lessons from the World's Most Captivating Presenters
Martafy!
 
What Would Steve Do? 10 Lessons from the World's Most Captivating Presenters
What Would Steve Do? 10 Lessons from the World's Most Captivating PresentersWhat Would Steve Do? 10 Lessons from the World's Most Captivating Presenters
What Would Steve Do? 10 Lessons from the World's Most Captivating Presenters
HubSpot
 
Hype vs. Reality: The AI Explainer
Hype vs. Reality: The AI ExplainerHype vs. Reality: The AI Explainer
Hype vs. Reality: The AI Explainer
Luminary Labs
 

Viewers also liked (6)

Pirineo
PirineoPirineo
Pirineo
 
Smart Start Annual Report FY11-12
Smart Start Annual Report FY11-12Smart Start Annual Report FY11-12
Smart Start Annual Report FY11-12
 
Advocacy presentation
Advocacy presentationAdvocacy presentation
Advocacy presentation
 
What Would Steve Do? Lessons from the World's Most Captivating Presenters
What Would Steve Do? Lessons from the World's Most Captivating PresentersWhat Would Steve Do? Lessons from the World's Most Captivating Presenters
What Would Steve Do? Lessons from the World's Most Captivating Presenters
 
What Would Steve Do? 10 Lessons from the World's Most Captivating Presenters
What Would Steve Do? 10 Lessons from the World's Most Captivating PresentersWhat Would Steve Do? 10 Lessons from the World's Most Captivating Presenters
What Would Steve Do? 10 Lessons from the World's Most Captivating Presenters
 
Hype vs. Reality: The AI Explainer
Hype vs. Reality: The AI ExplainerHype vs. Reality: The AI Explainer
Hype vs. Reality: The AI Explainer
 

Similar to Rx15 ea wed_300_1_perry-martin_2wethington

Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramseyRx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
OPUNITE
 
Ea 1 bullard cawhtorne_ taylorpowell_heeke
Ea 1 bullard cawhtorne_ taylorpowell_heekeEa 1 bullard cawhtorne_ taylorpowell_heeke
Ea 1 bullard cawhtorne_ taylorpowell_heekeOPUNITE
 
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwards
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwardsRx15 ea tues_330_1_lovedale_2holton_3varney-edwards
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwards
OPUNITE
 
Substance Abuse Baraga, Michigan
Substance Abuse Baraga, MichiganSubstance Abuse Baraga, Michigan
Substance Abuse Baraga, Michigan
recoveryrestart2
 
Rx15 le wed_1115_1_meinhofer_2simon-worthy
Rx15 le wed_1115_1_meinhofer_2simon-worthyRx15 le wed_1115_1_meinhofer_2simon-worthy
Rx15 le wed_1115_1_meinhofer_2simon-worthy
OPUNITE
 
Rx15 clinical wed_300_1_baier_2desrosiers_3hawkinberry-paxton
Rx15 clinical wed_300_1_baier_2desrosiers_3hawkinberry-paxtonRx15 clinical wed_300_1_baier_2desrosiers_3hawkinberry-paxton
Rx15 clinical wed_300_1_baier_2desrosiers_3hawkinberry-paxton
OPUNITE
 
Ea 4 cline raduka_wood
Ea 4 cline raduka_woodEa 4 cline raduka_wood
Ea 4 cline raduka_wood
OPUNITE
 
Tuesday astho
Tuesday asthoTuesday astho
Tuesday astho
OPUNITE
 
Addiction Medicine: Closing the Gap between Science and Practice
Addiction Medicine: Closing the Gap between Science and PracticeAddiction Medicine: Closing the Gap between Science and Practice
Addiction Medicine: Closing the Gap between Science and Practice
Center on Addiction
 
Rx15 tpp tues_330_1_gavin_2nader_3jeter
Rx15 tpp tues_330_1_gavin_2nader_3jeterRx15 tpp tues_330_1_gavin_2nader_3jeter
Rx15 tpp tues_330_1_gavin_2nader_3jeter
OPUNITE
 
Tpp 1 walls abou_nader
Tpp 1 walls abou_naderTpp 1 walls abou_nader
Tpp 1 walls abou_nader
OPUNITE
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
OPUNITE
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
OPUNITE
 
Rx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willisRx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willis
OPUNITE
 
Are You Ready for EPCS? Becoming mandatory before you know it.
Are You Ready for EPCS?  Becoming mandatory before you know it.Are You Ready for EPCS?  Becoming mandatory before you know it.
Are You Ready for EPCS? Becoming mandatory before you know it.
David Lovelace, CPHIMS, MHSA
 
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
Forward360 LLC
 
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbinsRx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
OPUNITE
 
Rx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williamsRx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williams
OPUNITE
 
Probation Parole Appa Jan Feb2010
Probation Parole Appa Jan Feb2010Probation Parole Appa Jan Feb2010
Probation Parole Appa Jan Feb2010Gilbert Gonzales
 
General Counsel Select, healthcare analytical
General Counsel Select,  healthcare analyticalGeneral Counsel Select,  healthcare analytical
General Counsel Select, healthcare analytical
Jean-Paul de Laureal
 

Similar to Rx15 ea wed_300_1_perry-martin_2wethington (20)

Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramseyRx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
 
Ea 1 bullard cawhtorne_ taylorpowell_heeke
Ea 1 bullard cawhtorne_ taylorpowell_heekeEa 1 bullard cawhtorne_ taylorpowell_heeke
Ea 1 bullard cawhtorne_ taylorpowell_heeke
 
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwards
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwardsRx15 ea tues_330_1_lovedale_2holton_3varney-edwards
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwards
 
Substance Abuse Baraga, Michigan
Substance Abuse Baraga, MichiganSubstance Abuse Baraga, Michigan
Substance Abuse Baraga, Michigan
 
Rx15 le wed_1115_1_meinhofer_2simon-worthy
Rx15 le wed_1115_1_meinhofer_2simon-worthyRx15 le wed_1115_1_meinhofer_2simon-worthy
Rx15 le wed_1115_1_meinhofer_2simon-worthy
 
Rx15 clinical wed_300_1_baier_2desrosiers_3hawkinberry-paxton
Rx15 clinical wed_300_1_baier_2desrosiers_3hawkinberry-paxtonRx15 clinical wed_300_1_baier_2desrosiers_3hawkinberry-paxton
Rx15 clinical wed_300_1_baier_2desrosiers_3hawkinberry-paxton
 
Ea 4 cline raduka_wood
Ea 4 cline raduka_woodEa 4 cline raduka_wood
Ea 4 cline raduka_wood
 
Tuesday astho
Tuesday asthoTuesday astho
Tuesday astho
 
Addiction Medicine: Closing the Gap between Science and Practice
Addiction Medicine: Closing the Gap between Science and PracticeAddiction Medicine: Closing the Gap between Science and Practice
Addiction Medicine: Closing the Gap between Science and Practice
 
Rx15 tpp tues_330_1_gavin_2nader_3jeter
Rx15 tpp tues_330_1_gavin_2nader_3jeterRx15 tpp tues_330_1_gavin_2nader_3jeter
Rx15 tpp tues_330_1_gavin_2nader_3jeter
 
Tpp 1 walls abou_nader
Tpp 1 walls abou_naderTpp 1 walls abou_nader
Tpp 1 walls abou_nader
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
 
Rx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willisRx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willis
 
Are You Ready for EPCS? Becoming mandatory before you know it.
Are You Ready for EPCS?  Becoming mandatory before you know it.Are You Ready for EPCS?  Becoming mandatory before you know it.
Are You Ready for EPCS? Becoming mandatory before you know it.
 
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
 
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbinsRx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
 
Rx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williamsRx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williams
 
Probation Parole Appa Jan Feb2010
Probation Parole Appa Jan Feb2010Probation Parole Appa Jan Feb2010
Probation Parole Appa Jan Feb2010
 
General Counsel Select, healthcare analytical
General Counsel Select,  healthcare analyticalGeneral Counsel Select,  healthcare analytical
General Counsel Select, healthcare analytical
 

More from OPUNITE

Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
OPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
OPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
OPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
OPUNITE
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
OPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
OPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
OPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
OPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
OPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
OPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
OPUNITE
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
OPUNITE
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
OPUNITE
 
Rx16 federal visionsession_200
Rx16 federal visionsession_200Rx16 federal visionsession_200
Rx16 federal visionsession_200
OPUNITE
 
Rx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenRx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2green
OPUNITE
 

More from OPUNITE (17)

Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
 
Rx16 federal visionsession_200
Rx16 federal visionsession_200Rx16 federal visionsession_200
Rx16 federal visionsession_200
 
Rx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenRx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2green
 

Recently uploaded

BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
GeoBlogs
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
BhavyaRajput3
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
MIRIAMSALINAS13
 

Recently uploaded (20)

BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
 

Rx15 ea wed_300_1_perry-martin_2wethington

  • 1. Education & Advocacy Track: Parent Advocates Moving Legislation Presenters: • Karen H. Perry, Co-Founder and Executive Director, Narcotics Overdose Prevention and Education (NOPE) Task Force, and Member, Rx Summit National Advisory Board • Gary R. Martin, EdD, Dean of Students, Lynn University, and Vice President, NOPE Task Force • Charlotte Wethington, MA, Recovery Advocate, Transitions, Inc. Moderator: Michael C. Barnes, JD, Executive Director, Center for Lawful Access and Abuse Deterrence (CLAAD), and Member, Rx Summit National Advisory Board
  • 2. Disclosures • Karen H. Perry; Gary R. Martin, EdD; Charlotte Wethington; and Michael C. Barnes, JD, have disclosed no relevant, real, or apparent personal or professional financial relationships with proprietary entities that produce healthcare goods and services.
  • 3. Disclosures • All planners/managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. • The following planners/managers have the following to disclose: – Kelly Clark – Employment: Publicis Touchpoint Solutions; Consultant: Grunenthal US – Robert DuPont – Employment: Bensinger, DuPont & Associates-Prescription Drug Research Center – Carla Saunders – Speaker’s bureau: Abbott Nutrition
  • 4. Learning Objectives 1. Identify state laws enacted as the result of parental advocacy. 2. Explain the purpose and components of the Overdose Prevention Act. 3. Describe Casey’s Law for involuntary treatment, as well as its passage, impact and applicability to other states.
  • 5. Parent Advocates Moving Legislation Karen H. Perry Co-Founder, Executive Director NOPE Task Force Gary R. Martin, Ed.D Dean of Students, Lynn University
  • 6. Disclosure Statement Karen Perry and Gary Martin have no financial relationships with proprietary entities that produce health care goods and services
  • 7. Learning Objectives 1. Identify state laws enacted as the result of parental advocacy. 2. Explain the purpose and components of the Overdose Death Prevention Act- “Richie’s Law” 3. Describe Casey’s Law for involuntary treatment, as well as its passage, impact and applicability to other states.
  • 11. Facts • In 2013, there were 35,663 unintentional drug overdose deaths in the United States. (Source: Center for Disease Control) • 2.5 million emergency department visits are attributed to drug misuse or overdose. (Source: Drug Abuse Warning Network (DAWN), 2011 National ED Estimates) • 26.8% of the people who died from a drug overdose had experienced a prior drug overdose with a hospital visit. (Source: Palm Beach County Sheriff’s Office Overdose Suppression Project 2013) • 82.3 % of the decedents had a known substance abuse history (Source: Palm Beach County Sheriff’s Office Overdose Suppression Project 2013) • 51.3 % of the decedents were under the care of a physician (Source: Palm Beach County Sheriff’s Office Overdose Suppression Project 2013)
  • 12. Heart Attack Victim Care The first 24 hours following a heart attack are usually spent in a coronary care unit (CCU) or an intensive care unit(ICU). Where skilled staff will: •Continuously monitor your heart rhythm •Administer a series of test and blood work •Administer medication as needed •Review patient’s history •Contact primary care and/or cardiac care physicians
  • 13. Cardiac Care Day Two If you remain stable after 24 hours You may be transferred to the "telemetry" floor of the hospital • Continue to receive care by a cardiac care team. • Depending upon the severity of the heart attack and how quickly you received treatment, you may be able to go home within two to four days.
  • 16. Overdose Death Prevention Act (ODPA) A bill that requires specific rules that would apply to an emergency care practitioner when the patient suffers a non-fatal unintentional overdose.
  • 17. ODPA Rules and Procedures • Proper medical stabilization (detox) • Substance Abuse Screening Brief Intervention and Referral to Treatment (SBIRT)
  • 18. ODPA Rules and Procedures • Notify patient’s primary care physician. • Notify all patient’s prescribing doctors within last 12 months.
  • 19. ODPA Rules and Procedures • Notify the patient’s emergency contact or next of kin. • Provide materials on addiction treatment, treatment facilities and practitioners. • Provide local involuntary treatment laws.
  • 20. HIPAA The HIPAA law currently indicates that emergency room physicians may notify next of kin if they feel it important or necessary for survival of the patient. This linked-document (authored by the U.S. Department of Health and Human Services) provides a summary of the HIPAA Privacy Rule. http://www.hhs.gov/ocr/privacy/hipaa/understanding/summary/in dex.html
  • 21. HIPAA Federal Register-Volume 65. No. 250 (12-28-2000) Section 164.502(g) – Personal Representatives “We continue to allow covered entities to use their discretion to disclose certain protected health care information to family members, relatives, close friends, and other persons assisting in the care of an individual, in accordance with 164.510(b). We recognize that many health care decisions take place on an informal basis, and we permit disclosures in certain circumstance to permit this practice to continue. Health care providers may continue to use their discretion to address these informal situations” (p. 82501).
  • 22. Readmissions Because Centers for Medicare & Medicaid Services will penalize hospitals that see too many patients return within a month, now is the time to create strategies to avoid readmissions.
  • 23. Local Overdose Death Data 247 drug overdose deaths in Palm Beach County in the year 2012 • More than Suicides • More than Homicides • More than Fatal Car Accidents
  • 24. Combining and Mixing Drugs • Multiple contributable drugs found in majority of overdose fatalities • Average of 2.7 drugs found in overdose cases
  • 25. 81 66 41 231 54 84 11 0 50 100 150 200 250 Cocaine Alcohol OTC Prescription Drugs Only Illicit Drugs Only Prescription and Illicit Drugs Not Toxicology NumberofDecedentswithDruginToxicology Toxicology Findings Compiled from 304 Closed Overdose Death Investigations
  • 26. 2 9 78 51 78 69 11 1 3 0 2 0 10 20 30 40 50 60 70 80 90 0-10 11-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 90-100 Unknown NumberofDecedents Years of Age Decedent's Age Data Compiled from 304 Closed Overdose Death Investigations
  • 28. 40.13% 32.57% 67.76% 38.16% 59.87% 48.68% 35.20% 17.43% 0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% 70.00% 80.00% Died in Municipality Taken to Hospital Died at Home Discovered by Family Died While Others Present Others Aware of Fatal Drug Use Others Recognized Victim's Distress Unusual Snoring Heard Circumstantial Variables Data Compiled from 304 Closed Overdose Death Investigations
  • 29. Education and Advocacy  Be informed of local issues  Build relationships  Educate Legislators and community partners  Create tool kit for community partners  Attend and provide testimonials at important legislative meetings
  • 30. Contact Information Karen H. Perry NOPE Task Force 561-478-1055 x201 kperry@nopetaskforce.org Gary Martin, Ed.D. Lynn University 561-237-7157 gmartin@lynn.edu
  • 31. Parent Advocates Moving Legislation Charlotte Wethington, MA Recovery Advocate Transitions, Inc.
  • 32. Disclosures • Charlotte Wethington, MA, has disclosed no relevant, real, or apparent personal or professional financial relationships with proprietary entities that produce healthcare goods and services.
  • 33.
  • 35.
  • 36.
  • 37.
  • 39. Matthew Casey Wethington Act for Substance Abuse Intervention
  • 40. What is Casey’s Law? • An involuntary treatment act in Kentucky for those who suffer from the disease of addiction
  • 41. History of the Act • Became a law on April 9, 2004 • Became effective July 13, 2004 in Kentucky • Inspired by the death of Matthew Casey Wethington, who died of a heroin overdose at the age of 23
  • 42. What does this law provide? Who can use the law? • A means of intervening with someone who is unable to recognize his or her need for treatment due to their impairment • Parents, relatives and/or friends can petition the court for treatment on behalf of the person who is impaired
  • 43. First Step • Obtain the petition from: – Your local Circuit Court Clerk’s Office – ask for Ask for the Verified Petition for Involuntary Treatment (Alcohol/Drug Abuse) otherwise known as form AOC 700A – www.caseyslaw.org
  • 44. Definitions for Completing the Petition Respondent Petitioner • The person needing substance abuse intervention • The person seeking to involuntarily commit someone else into treatment
  • 45. Steps for Completing the Petition • Step One: Enter the Respondent’s name, address and physical residence • Step Two: Enter Petitioner’s name, address and physical residence • Check box that corresponds with Petitioner's relationship to the Respondent • Step Three: Check box that corresponds with Petitioner's relationship to the Respondent
  • 46. Steps for Completing the Petition • Step Four: List the name, address and residence of persons related to the Respondent • Step Five: Provide all evidence Petitioner has that Respondent has an alcohol/drug abuse issue • Step Six: Attach additional sheets of paper if needed
  • 47. Evidence for Alcohol/Drug Abuse • Witnessing intoxication • Witnessing drug use • Behavioral changes • Failing drug screens • Criminal substance abuse charges • Theft • Track marks • Loss of interest • Occupational, social issues • Admitting alcohol/drug issue • Changes in physical appearance
  • 48. Steps for Completing the Petition • Step Seven: Provide all evidence to support why Petitioner believes the Respondent is a danger or threat of danger to self, family or others • Attach additional sheets of paper if needed
  • 49. Evidence of Threat • Respondent has threatened or talked of suicide • Respondent has threatened or talked of harming others (homicide) • Respondent is unable to provide basic survival needs (homeless, unemployed) • History of driving while intoxicated • Theft (breaking into homes, stealing from others…) • History of Overdose
  • 50. Steps for Completing the Petition • Indicate what length of treatment the Petitioner is seeking • Involuntary treatment for: – 60 consecutive days or less – 360 consecutive days or less • Sign and date the petition • Swear before the Court Clerk (staff) that all in the petition is true • Petition is then presented to a District Court Judge • The District Court Judge will then decide if there is just cause to continue with the petition
  • 51. The Final Step in Filing • By signing the petition, the petitioner guarantees payment for ALL COSTS incurred on behalf of the respondent • This includes but is not limited to the initial evaluations, transportation and placement in a treatment program
  • 52. What Now? • If the Judge agrees that there is just cause he/she will: • Set a hearing date • Order the Respondent to be examined by both a Licensed Physician and a Qualified Health Professional (Psychiatrist, CADC, LCSW, LRN) ** (Most counties require the names of the two evaluators upon filing the petition) **
  • 53. The Hearing • The hearing must be conducted within 14 days of the Petition being signed by the Judge • The Judge can chose to set the date sooner if the examinations can be completed • Or the Judge can extend the hearing date if a problem with the evaluations arise • The Respondent will be represented by legal counsel on the day of the hearing
  • 54. Summons of Involuntary Treatment • The Respondent is then notified to attend both examinations and to appear at the scheduled hearing • The Respondent can request that a Qualified Health Professional (at the Respondents expense) be permitted to witness and participate in their examinations • The Respondent is also notified that failure to comply with this summons may result in being held in contempt of court
  • 55. Appointment of Counsel • A public defender is appointed to represent the Respondent and is obligated to represent the desires of the Respondent
  • 56. Examinations • The Petitioner is responsible for the cost and the selection of the two evaluators, one of which must be a physician • Have the examination appointments set when filing the petition • If the Respondent does not keep the scheduled appointments he/she can be held in contempt of court
  • 57. Examinations • The Judge may order that the Respondent be held on a 72 hour hold if he/she feels the Respondent is in imminent danger • The Petitioner is responsible for all fees associated with the cost of evaluations
  • 58. Certification of Qualified Health Professional • This form is completed by the professional completing each examination • It is then sent to the court no longer than twenty-four (24) hours prior to the hearing • This also provides the professional’s recommendations for treatment
  • 59. At the Hearing • The Judge will examine all evidence including but not limited to: – Respondent’s testimony – Petitioner’s testimony – Examination reports
  • 60. Judgment and Order for Involuntary Treatment The Court will be looking for three things: 1. Does the Respondent suffer from alcohol and/or other drug abuse; and 2. Does the Respondent present an imminent threat of danger to self, family or others as a result of alcohol and other drug abuse; and 3. Can the Respondent reasonably benefit from treatment?
  • 61. Judgment and Order for Involuntary Treatment • If the Judge feels that all three criteria are met, then the Judge will order treatment • Since the Petitioner is responsible for payment of any ordered treatment, the Petitioner also chooses where the Respondent will complete treatment
  • 62. Judgment and Order for Involuntary Treatment • The Judge determines who will be responsible for transportation of the Respondent to the treatment program • If the Judge orders the Sheriff’s office to transport, then the Petitioner may be responsible for reimbursement to the Sheriff’s office for the cost of transportation
  • 63. Noncompliance • So what happens if the Respondent fails to complete anyone of these steps? • The respondent may be held in Contempt of Court • Contempt of Court is punishable in jail by any length of time the Judge sets each time the Respondent does not complete the Judge’s orders
  • 64. Passion + Purpose + Persistence= Power
  • 66. Charlotte Wethington, M.A. Recovery Advocate Transitions Inc. cwethington@transitionsky.org http://caseyslaw.org/ https://www.facebook.com/caseywethingtonact